Skip to main content
OpenTrials
Completed

NCT Number: NCT00792376

"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"

The purpose of this study is to evaluate etoricoxib efficacy in pain control, leg stiffness and functional recovery of patients suffering acute Achilles tendinopathy.

It is hypothesized that etoricoxib (120mg orally/day/7 days) efficacy is not inferior to diclofenac (150mg orally /day/7 days) for pain control in subjects suffering acute Achilles tendinopathy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Argentine Tennis Association

Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients are eligible if they are male between 18 and 50 years of age and they suffer acute Achilles tendinopathy (<2 weeks). Diagnosis of Achilles tendinopathy is made by means of activity-related achillodynia, morning stiffness or pain, painful one-legged jumping test, tenderness and decreased sports performance (26). Subjects' age, race, affected tendon (right, left), activity, height and weight will be recorded.

Exclusion criteria

  • Patients are excluded from the study if they have:
  • Prior lower limb surgery or major trauma.
  • Bilateral Achilles tendinopathy.
  • History of lower limb radiculo-neuropathy or miopathy.
  • Hypersensitivity to any NSAIDs.
  • Used analgesic agents (NSAIDs, salicilates, narcotic) within 1 week
  • Concurrent medical/arthritic disease (e.g. gout, lupus, rheumatoid arthritis).
  • Other concurrent medical conditions including diabetes, hypertension, angina or congestive heart failure, ischaemic cardiopathy, malabsorption, morbid - Personal history of renal dysfunction, hepatic dysfunction or anemia
  • Used corticosteroids, clopidogrel bisulphate, rifampin, quinolon antibiotics, antiepileptics, muscle relaxants, warfarin, ticlopidine, glucosamine, condroitin sulphate for < 6 months prior to the study start. Patients taking low dose aspirin (100 mg) for cardioprotective benefit will be also excluded. Any other medication consumption will be considered by the investigator and the Ethical Committee.
  • Any other condition which, in the opinion of the investigator, could confound the study results or pose a risk to the patient (for example, co-morbid conditions for which NSAIDs are contraindicated).
  • History of psychotic illness, dementia or depression
  • History of drug or alcohol abuse or dependence.
  • Participated in any previous NSAIDs study and received active treatment, or in an investigational trial within 30 days prior to the first visit.
  • Inability to communicate or to cooperate with the investigator.

Treatment and study plan

Etoricoxib

Drug

etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days

Diclofenac

Drug

diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.

Primary outcomes

  1. The pre-defined primary efficacy endpoint of the study is a 100-mm pain visual analog scale (P-VAS), where 0= no pain; 100= extreme pain.

    Time frame: 1 week

Secondary outcomes

  1. The secondary study endpoints includes: the VISA-A Questionnaire, the Achilles Tendinopathy Scoring System (ATSS), PGART using a 5-point Likert scale and leg functional stiffness.

    Time frame: 1 week

Sponsors and collaborators

Lead sponsor

Argentine Tennis Association

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Important dates

Study start
2009
Primary completion
2011
Study completion
2012
First posted
Nov 17, 2008
Registry last updated
Aug 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.